abc2xyz ，
Dun surrender ,you still can make some kopi money 1 or 2 cents.I told you before this counter got CE Mark.,
LP Mark and LC Mark.so please careful.
abc2xyz ( Date: 14-Oct-2008 15:34) Posted:
XiaoMaGe,
Comparing with other counters BIG is grossly underperforming. Remember before crisis and now after bailout, this counter really stinks. Most active counters and heavy weights have already recovered much ground but BIG loses grounds instead... Something must be wrong! Where is the confidence? Think I must consider surrender and switch counter. |
|
Now,0.275 liao,always same good news release price down.
Dun think Co.can help you, pease help yourself.
#$%@**&%#@
abc2xyz ( Date: 14-Oct-2008 14:57) Posted:
|
These few sessions buy low sell high made some profits of abt 2k.Don't know worth it or not? Not easy to loon loon until profit... Palm of hands sweating alot. Not like DBS, no need nervous, just buy and wait one or two days, you already got profit.
BIG Geeup..geeup, BIG, gee...UP. Don't be a LP share, please. I still have few lots.
XiaoMaGe888 ( Date: 14-Oct-2008 14:42) Posted:
| This LP Mark got pfofit make first. |
|
|
|
These few sessions buy low sell high made some profits of abt 2k.Don't know worth it or not? Not easy to loon loon until profit... Palm of hands sweating alot. Not like DBS, no need nervous, just buy and wait one or two days, you already got profit.
BIG Geeup..geeup, BIG, gee...UP. Don't be a LP share, please. I still have few lots.
XiaoMaGe888 ( Date: 14-Oct-2008 14:42) Posted:
| This LP Mark got pfofit make first. |
|
U r right. Now the stock is dancing Tango. 1 step forward, 2 step sideway & 3 step behind. Ha Ha HA !!!!
It is the confidence that whate the retail investors want from the mgt lah!!! SUPPORT the share value
01550615 ( Date: 14-Oct-2008 14:04) Posted:
So below the results are out, U can't do it, but what about after the result release... I'm sure U r not bind after it??? |
|
So below the results are out, U can't do it, but what about after the result release... I'm sure U r not bind after it???
BIG Management can not do that because of the TCT 2008 conference. There is some press release coming out from them like the below one.
01550615 ( Date: 14-Oct-2008 13:45) Posted:
| Take a look at UFB, the CEO take a plunge to buy 3mils of the co. share to boost up confidence. That what I meant by supporting the share value. Obviously producing good quality product result is a must for all co. Nevertheless, mgt must also support share value... |
|
Take a look at UFB, the CEO take a plunge to buy 3mils of the co. share to boost up confidence. That what I meant by supporting the share value. Obviously producing good quality product result is a must for all co. Nevertheless, mgt must also support share value...
That is precisely the point, I'm sure with this pricing it is definitely better than their stock option...If th mgts is interested in the share value, I'm sure they can afford to put some investment not withstanding that they keep promoting & optimistic about the future of the product & co.
medical companies are usually cash intensive, buy backs with cash could lead to unnecessary increase in debt leverage and failure to meet short term loans (see the once mighty Ferrochina). Its better for BIG to preserve cash (for funding of research) and ask directors to buy instead
As I said, if U want the price to move up, the mgt needs to support buying...so to give confidence in what they say & do
...
Can't even bring back yesterday loss. Tai wok counter. Really hv to hope for miracle liao, though vested some.
Abbott, Boston Scientific Stents Tie in Safety Study (Update1)
By Alex Nussbaum
Oct. 13 (Bloomberg) --
Abbott Laboratories' Xience and
Boston Scientific Corp.'s Taxus Liberte, the newest entrants in the $1.9 billion U.S. market for heart stents, dueled to a tie in a study of heart attack victims.
The two stents were ``equally efficient'' over six months, according to researchers at a Washington, D.C.,
medical conference yesterday. An increase in deaths in Xience patients was driven by factors unrelated to the devices, they said.
The results are another boost for Abbott Park, Illinois- based Abbott, whose artery-clearing Xience stent has been gaining ground on rivals since it was approved for sale July 2. Boston Scientific's Liberte, cleared on Oct. 10, will need to prove superior in new human trials to expand market share, said
Philip Nalbone, an RBC Capital Markets analyst in San Francisco.
Otherwise, Liberte ``won't make a difference,'' Nalbone said in an interview before the study was released.
Stents are metal tubes that prop open an artery after it's cleared of fatty deposits called plaque. Newer versions of the $2,000 devices are coated with drugs to prevent scar tissue that can reblock the blood vessel.
The newly approved Liberte joins Xience,
Medtronic Inc.'s Endeavor and
Johnson & Johnson's Cypher in an increasingly crowded market. Boston Scientific, based in Natick, Massachusetts, also sells a version of Xience called Promus under a licensing deal that gives Abbott 40 percent of profit.
40% of Market
Since debuting in July, Xience and Promus have captured 40 percent of the U.S. stent market, said
Rick Wise, a Leerink Swann & Co. analyst, in an Oct. 10 note citing a survey of cardiologists. The number is likely to rise to 50 percent by next July, with Abbott's version claiming almost three-quarters of sales, Wise wrote.
Doctors predicted Boston's Taxus line of stents will stay steady at 29 percent over the next year, even with Liberte.
In a study of 335 heart attack victims,
3.2 percent of patients given a Xience stent died within a month compared with 1.3 percent of Taxus Liberte users, according to researchers at Rotterdam's
Medical Centre Rijnmond-South. At six months, with 185 people left in the trial, the figures were
6.9 percent and 2.3 percent, respectively.
The studies, funded by the hospital, were presented yesterday at the Transcatheter Cardiovascular Therapeutics conference.
The discrepancies resulted from deaths unrelated to the devices, according to a summary of the study from conference organizers. The trial, called COMPARE, is still following patients.
Boston Scientific soared $1.25, or 17 percent, to $8.56 at 10:11 a.m. in New York Stock Exchange composite trading after earlier rising 27 percent, its biggest gain since selling shares to the public in 1992. Abbott rose $2.26, or 4.6 percent, to $51.71, and earlier jumped 6.7 percent, the most since Dec. 31, 2002.
Drug-coated stents accounted for 35 percent of Boston Scientific's $2.02 billion in revenue in the second quarter this year. They generated 3 percent of Abbott's $7.3 billion quarterly income.
>> i wonder if these results are somehow skewed to show that Taxus Liberte is better. Anyway, 6.9% for Xience is freaking high compared to Liberte's 2.3%! I would still like to see some independent trial done to compare all these stents. Someone is probably lying. If the result is true, then Xience is not that fantastic after all..
Post Reply
5541-5560 of 10899